Immutep announces first-in-human phase I study of IMP761

Immutep announces that the first part of the placebo-controlled, double-blind first-in-human Phase I study evaluating IMP761 has been fully recruited and the drug has been administered with no safety issues. The trial being conducted by the Centre for Human Drug Research, CHDR, in Leiden, the Netherlands, has now progressed to the Part B dose escalation phase with single IMP761 dosing planned to move from 0.03 mg/kg up to 0.90 mg/kg. Both safety and pharmacokinetic/pharmacodynamic, PK/PD, modeling will be assessed in this second cohort of healthy volunteers. Pending no safety issues, the trial will then shift to the multiple ascending dose portion in 14 subjects in which PK will be further evaluated.